Brilaroxazine NDA Delayed as FDA Requires Additional Phase 3 Trial for Schizophrenia Drug
Summary
Reviva Pharmaceuticals announced that the FDA has recommended a second Phase 3 clinical trial for its lead schizophrenia drug candidate, brilaroxazine, to generate additional efficacy and safety data prior to NDA submission. This requirement significantly delays the potential market entry and increases the development costs for the company's primary asset. The company also reported full year 2025 financial results, though specific financial figures were not provided in the release. This regulatory setback comes shortly after Reviva completed a $10 million dilutive public offering in mid-March, suggesting that further capital raises will likely be necessary to fund the additional trial, putting more pressure on the stock.
At the time of this announcement, RVPH was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.67 to $23.20. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.